Stemline Therapeutics (NASDAQ:STML) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

Other research analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. ValuEngine raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Stemline Therapeutics in a research report on Friday, November 10th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $33.75.

Stemline Therapeutics (NASDAQ STML) traded up $0.25 during trading on Wednesday, hitting $14.10. 100,595 shares of the stock traded hands, compared to its average volume of 214,886. The stock has a market capitalization of $356.55, a P/E ratio of -5.49 and a beta of -0.02. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $16.20.

In related news, COO Kenneth Hoberman sold 11,943 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $14.18, for a total transaction of $169,351.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 37,966 shares of company stock valued at $534,848. 16.70% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. C WorldWide Group Holding A S acquired a new stake in shares of Stemline Therapeutics during the third quarter worth approximately $1,776,000. Northern Trust Corp boosted its holdings in shares of Stemline Therapeutics by 18.0% during the second quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock worth $2,529,000 after purchasing an additional 41,898 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Stemline Therapeutics by 74.9% during the second quarter. Dimensional Fund Advisors LP now owns 120,477 shares of the biopharmaceutical company’s stock worth $1,108,000 after purchasing an additional 51,578 shares during the period. Lyon Street Capital LLC lifted its stake in Stemline Therapeutics by 331.1% in the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after acquiring an additional 415,867 shares during the last quarter. Finally, Cowen Inc. acquired a new stake in Stemline Therapeutics in the third quarter valued at approximately $420,000. Institutional investors and hedge funds own 50.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2018/01/14/stemline-therapeutics-stml-cut-to-hold-at-bidaskclub.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.